$LDOS

Geer Noel B sold $1.4M of LDOS

Geer Noel B sold 10,000 shares of Leidos Holdings, Inc. (LDOS) at an average of $140.66 ($140.59–$141.07, $1.41M total) across 2 trades on 2026-08-11.

Original reporting
SEC EDGAR · Geer Noel B
Published Aug 13, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LDOS
Neutral
medium confidence
Mentioned
$LDOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LDOSNeutralLow
01

Why it matters

Traders may monitor for clustering of insider activity or subsequent filings, but this single sale does not, by itself, change valuation drivers.

02

Market read

A newly filed insider sale provides incremental sentiment information, but no new company fundamentals are disclosed.

03

What to watch

The article provides only the sale details; it does not include context on total compensation, prior holdings, or whether other insiders are selling or buying around the same time.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed after-hours on 2026-08-13, covering sales dated 2026-08-11.

Background

The article is an SEC Form 4 insider transaction disclosure for Leidos Holdings, Inc. (LDOS).

Company-level read

Ticker impact

$LDOSNeutralMedium confidence
Context

Leidos director Geer Noel B sold 10,000 shares in open-market trades at about $140.66 per share, per a fresh SEC Form 4 filing.

Expected impact

Likely limited, with any effect confined to short-term sentiment unless follow-on filings or company news emerge.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific operational or guidance update in the text.

Market effects

Minimal, since the disclosure is company-specific and does not indicate sector-wide contract or regulatory changes.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated versus the absence of a 10b5-1 plan.

Key entities

  • Leidos Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Geer Noel B

    Director who sold 10,000 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LDOSMedAI 9/10

Infrastructure Acquisition. Is This a Quiet AI Winner?

Leidos (NYSE: LDOS) reported Q3 revenue of $4.6B (+7% YoY) and raised 2026 guidance to $18.2B-$18.4B revenue, $12.20-$12.50 EPS. It acquired ENTRUST for $2.4B, expanding energy infrastructure. Near-term margins may dip due to acquisition costs, but long-term growth is expected from AI data center energy demand.

$AZNHighAI 8/10

AstraZeneca, Leidos, Expeditors International: CNBC ‘Final Trades’ - Expeditors International (NYSE:EXPD)

CNBC's 'Final Trades' featured picks from Jim Lebenthal (AstraZeneca, AZN), Stephen Weiss (Leidos, LDOS), Liz Thomas (Treasuries), and Joseph Terranova (Expeditors, EXPD). AZN reported regulatory approvals and strong trial data, LDOS beat Q2 estimates and raised guidance, and EXPD also exceeded Q2 expectations. Shares of AZN, LDOS, and EXPD rose 2.3%, 3.1%, and 0.5% respectively on Monday.

$LDOSMedAI 9/10

LDOS Looks 22.8% Undervalued on GF Value™

Leidos Holdings Inc (LDOS) secured an $875M contract extension from the U.S. Navy. The stock is trading at $132.83, 22.8% below its GF Value™ of $171.99, indicating undervaluation. LDOS has a GF Score™ of 78/100, reflecting strong financial health and profitability. Insiders sold $3.2M in shares over the past year.